Skip to main content
. 2023 Feb 18;21:53. doi: 10.1186/s12957-023-02939-5

Table 2.

Summary of treatment

Patient no. TKIs + ICIs TACE/RFA
1–21 Len + Sin ~
22–31 Len + Sin TACE
32 Len + Sin TACE + RFA
33–34 Len + Pem ~
35–36 Len + Pem TACE
37 Len + Niv ~
38–39 Len + Niv TACE
40–41 Len + Niv TACE + RFA
42 Apa + Pem ~
43 Apa + Sin ~
44 Apa + Sin TACE

TKIs tyrosine kinase inhibitors, Len lenvatinib, Apa apatinib, Sin sintilimab, Pem pembrolizumab, Niv nivolumab, TACE trans-arterial chemoembolization, RFA radiofrequency ablation, ~ none